The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Hendrik Ungefroren; Björn Konukiewitz; Ulrich F Wellner; Jörg Schrader; Tobias Keck

doi:10.3390/cancers15010160

The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Hendrik Ungefroren
Björn Konukiewitz
Ulrich F Wellner
Jörg Schrader
Tobias Keck

Related Research units

I. Medical Clinic and Polyclinic

Abstract

Pancreatic neuroendocrine neoplasms (pNENs) account for approximately 5% of all pancreatic tumors; thus, they constitute the second most common tumor type in the pancreas [...].

Bibliographical data

Original language	English
Article number	160
ISSN	2072-6694
DOIs	https://doi.org/10.3390/cancers15010160
Publication status	Published - 27.12.2022

PubMed	36612156